Mankind Pharma Faces Continued Stock Decline Amid Broader Market Trends

Mankind Pharma, a prominent player in the Pharmaceuticals & Biotechnology sector, has experienced a notable decline of 3.05% on May 22, 2025. This downturn marks the fourth consecutive day of losses for the stock, which has seen a total drop of 4.56% over this period. The stock opened lower today, with an initial loss of 2.88%, and reached an intraday low of Rs 2451, reflecting a decrease of 3.24%.
In terms of performance metrics, Mankind Pharma has underperformed compared to its sector, lagging by 2.47%. Over the past week, the stock has declined by 3.86%, while the broader market, represented by the Sensex, has fallen by 2.06%. Over the past month, Mankind Pharma's performance has dipped by 4.80%, contrasting with the Sensex's gain of 1.55%. However, on a longer-term basis, the stock has shown resilience, with a 5.29% increase over the last three months and a 16.29% rise over the past year, significantly outperforming the Sensex's 8.90% increase during the same timeframe.

Despite the recent challenges, Mankind Pharma remains above its 50-day moving average, although it is currently below its 5-day, 20-day, 100-day, and 200-day moving averages.